Joseph E. Payne serves as the President, Chief Executive Officer, and Director at Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company. With a strong background in biotechnology and pharmaceuticals, Payne has been instrumental in guiding Arcturus through significant growth and development. He joined the company in 2017 and has since led the organization in advancing its pipeline of mRNA-based therapeutics and vaccines, focusing on rare diseases and infectious diseases. Prior to his role at Arcturus, Payne held several high-level positions in the industry. He was the President and CEO of Lumena Pharmaceuticals, where he successfully led the company through its acquisition by Shire Pharmaceuticals in 2014. Before Lumena, Payne served as Senior Vice President and Chief Business Officer at Auspex Pharmaceuticals, which was later acquired by Teva Pharmaceutical Industries. His extensive experience in strategic planning, business development, and corporate leadership has been pivotal in driving Arcturus' mission to develop transformative medicines. Under Payne's leadership, Arcturus has made significant strides in its clinical programs, including advancing its lead candidate, ARCT-810, for the treatment of ornithine transcarbamylase deficiency, a rare genetic disorder. Additionally, Payne has overseen the company's efforts in developing a COVID-19 vaccine candidate, showcasing Arcturus' capabilities in responding to global health challenges. His strategic vision and commitment to innovation continue to position Arcturus as a frontrunner in the mRNA therapeutics space.